Tracon Pharmaceuticals has terminated the Phase II ENVASARC trial for its sarcoma therapy, envafolimab, as the therapy is unlikely to show the level of efficacy required to support a biologics licence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results